TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(UCLA Health), Elena Bitman(Massachusetts General Hospital), Beverly Moy(Global Cancer Institute), Laura M. Spring(Massachusetts General Hospital), Bogang Wu(George Washington University), Geoffrey Fell(Dana-Farber Cancer Institute), Seth A. Wander(Harvard University), Bryanna L. Norden(Massachusetts General Hospital), Ryan B. Corcoran(Massachusetts General Hospital), Andreas Varkaris(Massachusetts General Hospital), Neelima Vidula(Harvard University), Win Thant(Massachusetts General Hospital), Haley Barnes(Massachusetts General Hospital), Leif W. Ellisen(Harvard University), Caroline Weipert(Guardant (United States)), Dejan Juric(Massachusetts General Hospital), Annika Putur(Massachusetts General Hospital), Steven J. Isakoff(Harvard University), Ting Liu(National Institutes for Food and Drug Control), Arielle J. Medford(Harvard University)
Cited by 39
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k